Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
Status:
Withdrawn
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
In this single-center therapeutic study, we will study the ability of efalizumab to protect
remaining beta cells in teenagers and young adults who have been newly diagnosed with type 1
diabetes mellitus. Efalizumab is a monoclonal antibody which prevents the activation of
antigen specific T lymphocytes to sites of inflammation. Efalizumab was approved by the FDA
in 2003 for the treatment of psoriasis. It has been proven to be safe, well tolerated and
effective in targeting T cell mediated disorders like those seen in autoimmunity.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Genentech, Inc. Juvenile Diabetes Research Foundation